Avalo Therapeutics Analyst Ratings
RBC Capital Downgrades Avalo Therapeutics to Sector Perform, Lowers Price Target to $0.75
Avalo Therapeutics Downgraded by RBC to Sector Perform From Outperform, Price Target Cut to $0.75 From $9, Speculative Risk Kept
RBC Cuts Price Target on Avalo Therapeutics to $9 From $17, Maintains Outperform Rating, Speculative Risk Qualifier
Jefferies Downgrades Avalo Therapeutics to Underperform, Announces $3 Price Target
Avalo Therapeutics Analyst Ratings
Avalo Therapeutics (AVTX) Gets a Buy From RBC Capital
Oppenheimer Adjusts Avalo Therapeutics Price Target to $17 From $5, Maintains Outperform Rating
RBC Cuts Price Target on Avalo Therapeutics to $17 From $21, Maintains Outperform Rating, Speculative Risk Qualifier
RBC Cuts Price Target on Avalo Therapeutics to $21 From $24 After 1-for-12 Reverse Stock Split; Outperform, Speculative Risk Kept
No Data